BCL2 and inflammatory breast carcinoma: Ki-67 and BCL-2 expression was mostly observed in invasive breast carcinoma (IBC) and premenopausal patients (<50 years old) in this study, probably due to their proliferative and anti-apoptotic effect as well as an up-regulation related to higher hormonal levels, and hence higher receptors expression during this age period13,14,18,19.